Filing Flows › Foghorn Therapeutics (FHTX) › Q2 2026 › vs Q2 2025
Foghorn Therapeutics (FHTX) Q2 2026 vs Q2 2025 (year over year)
Foghorn Therapeutics's revenue rose $8.5M (+113%) from $7.6M in Q2 2025 to $16.1M in Q2 2026.
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $16.1M | $7.6M | $8.5M | +113% |
| Other income, net | $1.6M | $3.2M | −$1.5M | -49% |
| Net loss | $7.2M | $17.9M | −$10.7M | -60% |
| Costs & expenses | $24.9M | $28.7M | −$3.8M | -13% |
| Operating costs | $24.9M | $28.7M | −$3.8M | -13% |
| Research & development | $18.5M | $21.8M | −$3.3M | -15% |
| General & admin | $6.4M | $6.9M | −$508K | -7% |
| Operating cash sources | $20.6M | $24.6M | −$4.0M | -16% |
| Depreciation & amortization | $200K | $900K | −$700K | -78% |
| Share-based compensation | $2.5M | $2.7M | −$183K | -7% |
| Cash used in operations | $17.8M | $21.0M | −$3.2M | -15% |
| Net loss absorbed | $7.2M | $17.9M | −$10.7M | -60% |
| Working capital & other | $13.4M | $6.7M | $6.7M | +100% |
Questions
How much did Foghorn Therapeutics's revenue grow year over year in Q2 2026?
Foghorn Therapeutics's revenue rose $8.5M (+113%) from $7.6M in Q2 2025 to $16.1M in Q2 2026.